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Jakub Kwiecinksi3, Tao Jin3, Bart De Geest1, Marc F Hoylaerts1, Roger H Lijnen1 and Peter Verhamme1Abstract
Background: Staphylococcus aureus (S. aureus) is a frequent cause of skin and soft tissue infections. A unique
feature of S. aureus is the combined presence of coagulases that trigger fibrin formation and of the plasminogen
activator staphylokinase (SAK). Whereas the importance of fibrin generation for S. aureus virulence has been
established, the role of SAK remains unclear.
We studied the role of plasminogen activation by SAK in a skin infection model in mice and evaluated the impact
of alpha-2-antiplasmin (α2AP) deficiency on the spreading and proteolytic activity of S. aureus skin infections. The
species-selectivity of SAK was overcome by adenoviral expression of human plasminogen. Bacterial spread and
density was assessed non-invasively by imaging the bioluminescence of S. aureus Xen36.
Results: SAK-mediated plasmin activity increased the local invasiveness of S. aureus, leading to larger lesions with
skin disruption as well as decreased bacterial clearance by the host. Even though fibrin and bacterial surfaces
protected SAK-mediated plasmin activity from inhibition by α2AP, the deficiency of α2AP resulted in increased
bacterial spreading. SAK-mediated plasmin also induced secondary activation of gelatinases, shown both
in vitro and in lesions from the in vivo model.
Conclusion: SAK contributes to the phenotype of S. aureus skin infections by enhancing bacterial spreading
as a result of fibrinolytic and proteolytic activation.
Keywords: Fibrinolysis, Matrix metalloproteinases, Plasminogen, Staphylococcus aureus, Staphylokinase, Skin infectionBackground
Staphylococcus aureus (S. aureus) is the leading cause
of skin and soft tissue infections, both community- and
hospital-acquired [1,2]. S. aureus is a versatile pathogen
that has the intriguing capacity to modulate both the host’s
coagulation and fibrinolytic system.
We and others have shown that fibrin formation in-
duced by the bacterial prothrombin activators staphylo-
coagulase and von Willebrand factor-binding protein is
an important virulence factor for both localized and sys-
temic infections by S. aureus and is essential for abscess
formation [3-6]. Most S. aureus strains causing infection* Correspondence: marijke.peetermans@med.kuleuven.be
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unless otherwise stated.in humans also produce staphylokinase (SAK). SAK forms
an equimolar complex with human plasmin (huPli)
catalyzing the further activation of plasminogen. The SAK-
huPli complex is sensitive to rapid inhibition by alpha-2-
antiplasmin (α2AP) unless it is bound to fibrin via the
lysine binding sites of plasmin. This mechanism accounts
for the fibrin-specificity of SAK [7,8]. Although SAK has
received considerable research attention during its devel-
opment as a fibrinolytic agent in cardiovascular medicine
[7], few studies have investigated its relevance in S. aureus
infection [9,10].
Streptokinase, secreted by group A, C and G strepto-
cocci, is the other well-known bacterial plasminogen ac-
tivator. Like SAK, streptokinase is specific for human
plasminogen (huPlg) but its action is not inhibited by
α2AP [11]. Streptokinase is a key virulence factor and thentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Bacterial staphylokinase production. Staphylokinase
(SAK) production of different S. aureus strains after overnight culture,
as assessed by ELISA. SAK secretion of the bioluminescent strain
S. aureus Xen36 is comparable to relevant clinical S. aureus strains
from bacteremia with cutaneous origin and from skin infection. SAK
production of reference lab strains, including a SAK-negative (LS-1 EP)
and a SAK-overproducing (LS-1 spasak) S. aureus strain are included
as controls.
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A streptococcal infections. Mortality after infection with
group A streptococci is markedly increased in huPlg trans-
genic mice [12,13]. Interestingly, a subcluster of streptokin-
ase (type 2b) has been identified that is sensitive to α2AP
inhibition, leading to site-restricted plasminogen activation
in these, mostly skin-trophic, group A streptococci [14].
The role of SAK as a potential virulence factor in
S. aureus disease remains unresolved. SAK is present in
the large majority of S. aureus strains causing human in-
fection [15-24]. In contrast, S. aureus strains from veterin-
ary sources commonly lack SAK production [23,24]. SAK,
like streptokinase [25], thus constitutes an adaptation of
S. aureus for human infection. The sak gene has a highly
conserved sequence [26-29] and is carried on a bacterio-
phage containing other genes with an important function
in immune evasion, such as complement inhibitory factors
and enterotoxins [21,30]. SAK was shown to enhance the
breaching of tissue barriers in vitro [10].
The present study aimed at evaluating if plasmin gener-
ation by SAK impacts on proteolytic activity in S. aureus
infected skin and on the local and systemic dissemination
of S. aureus. We further investigated if the host α2AP, by
inhibiting the SAK-plasmin activity, reduces the virulence
of S. aureus.
Results
Bacterial staphylokinase production
Supernatant of overnight cultures of the bioluminescent
S. aureus Xen36 contained similar levels of SAK com-
pared to lab strains and to clinical S. aureus strains from
skin infection and from bacteremia with cutaneous ori-
gin. SAK expression by LS-1 spasak, which expresses
SAK under the control of the protein A promoter, was
about tenfold higher (Figure 1). Thus, S. aureus Xen36 is
a relevant micro-organism to study the role of SAK in a
skin infection model.
Skin infection model
Adenoviral-mediated human plasminogen expression
To overcome the species-selectivity of SAK for huPlg,
huPlg was expressed in mice through adenoviral gene
transfer. Seven to 11 days after adenoviral injection,
i.e. at the start of the subcutaneous infection experi-
ment, huPlg plasma values in Adplasm injected mice
were 31.6 ± 15.5 μg/ml in α2AP KO and 31.5 ± 10.1 μg/ml
in α2AP WT mice. In mice injected with the control
Adnull adenoviral vector, values of huPlg were below the
detection level (3 μg/ml). Human plasminogen remained
present until the end of the experiment (27.3 ± 10.0 μg/ml
at day 5 and 37.2 ± 29.6 μg/ml at day 10) (Figure 2).
Hence, the expression of huPlg allowed for the selective
interaction of SAK with huPlg throughout the course of
the subcutaneous infection experiment.Infectious skin lesions
After subcutaneous inoculation with S. aureus Xen36,
macroscopic lesion size was significantly larger in huPlg
expressing mice compared to control wild type mice
(33.6 ± 19.6 mm2 in WT/huPlg mice (n = 17) vs. 19.2 ±
9.7 mm2 in WT/null mice (n = 12) at day 10, P < 0.01)
(Figure 3A). The constitutive luciferase expression of S.
aureus Xen36 also allowed for non-invasive monitoring
of the spreading and density of the bacteria over time
(illustrated in Figure 3C). Expression of huPlg increased
both bacterial spreading (P < 0.05 on day 3, P < 0.01
on day 6 and 9) and bacterial load (P < 0.05 on day 3
and 9, P < 0.01 on day 6) early in the course of infec-
tion (Figures 3B and 3D).
Compared to wild type mice, bacterial spreading in
α2AP KO mice was similar in the early stages of the
infection, but was more pronounced at day 9 (P < 0.05)
(Figure 3B), resulting in an increase in macroscopic le-
sion size at day 10 (31.8 ± 20.9 mm2 in α2AP KO/null
mice (n = 11) vs. 19.2 ± 9.7 mm2 in WT/null mice (n = 12),
P = 0.078) (Figure 3A). Bacterial density was higher in
α2AP KO mice compared to wild type mice (P = 0.115 on
day 6, P < 0.05 on day 9) (Figure 3D). In an additional
experiment, α2AP KO or WT mice were infected with
S. aureus LS-1 EP. We observed similar initial fibrin de-
position in the abscess periphery in both groups at day 1
(Additional file 1), consistent with a normal capacity for fi-
brin formation in α2AP KO plasma ex vivo (data not
shown). However, at a later time point, less fibrin was ob-
served in α2AP KO mice, as shown in Additional file 1.
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Figure 2 Adenoviral-mediated human plasminogen expression. Human plasminogen (huPlg) expression in murine plasma after administration
of 5 × 1010 viral particles of adenoviral vector Adplasm. Day 0 is the day of subcutaneous infection with S. aureus Xen36, 7 to 11 days after adenoviral
injection. Values from Adnull injected mice are included as negative controls. The expression of huPlg during the whole course of the subcutaneous
infection experiment allows the selective interaction of staphylokinase with huPlg.
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with human plasminogen expression (42.9 ± 27.4 mm2 in
α2AP KO/huPlg (n = 14) vs. 19.2 ± 9.7 mm
2 in WT/null
(n = 12), P < 0.001) (Figure 3A). The spreading of the bac-
teria was more pronounced from early in the course of
infection (P = 0.137 on day 3, P < 0.01 on day 6 and 9)
(Figure 3B). Also the intensity of the bioluminescence,
which relates to the bacterial density, was the highest in
the α2AP KO/huPlg group (P = 0.153 on day 3, P < 0.01 on
day 6, P < 0.05 on day 9) (Figure 3D).
The assessment of systemic spread of S. aureus, by
quantifying bacterial load in spleen and kidney, did not
differ significantly between the 4 groups. At day 10, there
were 2 mice in the α2AP KO/huPlg group with distant
infection in spleen and/or kidney, 2 mice in the α2AP KO/
null group, 1 mouse in the WT/huPlg group and none in
the WT/null group.
In the first series of experiments, we observed that the
differentiation between the groups both in macroscopic
phenotype (open/closed lesion) and in bioluminescence
lesion size and intensity became apparent early in the
course of infection. Therefore, to assess macroscopic and
microscopic phenotype and proteolytic activity, mice were
sacrificed at day 3 in a subsequent set of experiments.
Macroscopical assessment confirmed closed abscesses
in WT/null mice, compared to more diffusely spread le-
sions with skin rupture in huPlg expressing mice (P < 0.01)
(Figure 4A-C).
Histopathologic analysis of lesional skin sections from
α2AP KO/huPlg mice showed, apart from breaching of
skin, penetration of infection starting from the initial in-
fection site, past a peripheral fibrin zone, into subdermal
tissue layers (Figure 4C-E).Mechanism of SAK action in S. aureus skin infections
SAK is species-selective and fibrin-specific
The observations in the subcutaneous infection model
can be explained by the SAK-mediated plasmin gener-
ation. To this end however, the values of huPlg achieved
after adenoviral huPlg expression in mice, should be able
to rescue the species-selectivity of SAK in a murine model.
SAK induced rapid plasmin generation if added to huPlg
but not with murine plasminogen (muPlg) (Figure 5A).
However, activation of muPlg was observed in the pres-
ence of SAK and trace amounts of human plasminogen
(Figure 5A). Also, addition of a preformed SAK-huPli
complex triggered secondary activation of muPlg, as illus-
trated in Figure 5B. For all further experiments, a mixture
of muPlg (0.25 μM) and huPlg (0.05 μM) was used to re-
flect the in vivo conditions of partial huPlg expression
against a background of muPlg.
SAK-mediated plasmin generation was further enhanced
in the presence of fibrin, as CnBr-digested fibrinogen frag-
ments (Fg(CNBr)) (Figure 5C-D) or as solid fibrin (data
not shown). For convenience, Fg(CNBr) was used in fur-
ther experiments, as an accepted soluble alternative to
solid fibrin. This increase in plasmin generation in the
presence of fibrin can be explained by a reduced inactiva-
tion of fibrin-associated SAK-huPli complex by α2AP. As
shown in Figure 5C, α2AP inhibited SAK-induced plasmin
generation in control conditions, but had little effect on
SAK-induced plasmin generation in the presence of
Fg(CNBr) (A405,60min of 0.853 ± 0.058 vs. 0.121 ± 0.005 for
SAK + Plg + α2AP, P < 0.01). Higher concentrations of
Fg(CNBr) completely protected SAK-induced plasmin
from inhibition by α2AP (A405, 60min of 1.036 ± 0.039 vs.
0.121 ± 0.005 for SAK + Plg + α2AP, P < 0.001) (Figure 5D).
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Figure 3 SAK-mediated plasmin activity increased infectious skin lesion size and bacterial load. A. Macroscopically apparent lesion size 10
days after subcutaneous inoculation with S. aureus Xen36. Mean and SD for skin lesions in WT/null mice (n = 12), α2AP KO/null mice (n = 11),
WT/huPlg mice (n = 17) and α2AP KO/huPlg mice (n = 14), respectively. B. Lesion size: S. aureus Xen36 possesses a stable copy of the modified
Photorhabdus luminescens luxABCDE operon. Evolution of bacterial spread was assessed non-invasively by bioluminescence image analysis of the
surface area with signal > threshold. Mean and SEM for lesion size in the 4 groups. Dimensions for α2AP KO/huPlg mice and WT/huPlg mice are
compared to WT/null mice. C. Examples of bioluminescence photographs of the left flank lesion for representative animals of the 4 groups at day 9.
D. Bacterial load: signal intensity of the infectious lesion site, in photons/s through a defined region of interest, which was used for all lesions. Bacterial
density analysis shows that bacterial clearance is hampered by enhanced proteolytic activity. Mean and SEM for signal intensity in the 4 groups.
Bacterial loads for α2AP KO/huPlg, α2AP KO/null and WT/huPlg mice are compared to WT/null mice. *denotes P < 0.05, **P < 0.01, ***P < 0.001.
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We also studied if, besides fibrin, bacterial surfaces could
protect the SAK-huPli complex from α2AP inhibition.
Indeed, the presence of bacteria increased plasmin gen-
eration following addition of SAK (A405, 90min 1.035 ±
0.076 vs. 0.675 ± 0.138, P < 0.05). Addition of murine
α2AP significantly reduced plasmin generation by ≈ 70%
to A405, 90min of 0.195 ± 0.034 (P < 0.05), whereas in the
presence of bacteria, α2AP only led to a ≈ 50% reduc-
tion in plasmin generation (A405, 90 min = 0.487 ± 0.094,
P < 0.01) (Figure 6). We used a SAK-negative S. aureus
strain (LS-1 EP) for this subset of experiments to elimin-
ate confounding by SAK production during the course of
the experiment. However, similar results were observed
for SAK-positive S. aureus Xen36, which was the strain
used in animal experiments. Comparable results were also
obtained when heat-killed instead of viable S. aureus was
used (data not shown).SAK-huPli complex activates gelatinases
Plasmin has a broad proteolytic spectrum that includes
extracellular matrix proteins. However, plasmin is also
known to activate gelatinases, which can cause secondary
proteolytic activity. In order to assess whether gelatinase
activation contributes to the observed bacterial spreading,
we measured the activation of gelatinases by SAK-huPli in
murine skin extracts.
Addition of SAK and huPlg to extracts of murine skin
led to activation of pro-MMP-2 (Figure 7A). In line with
the low expression of MMP-9 in normal non-inflamed
skin, pro-MMP-9 and active MMP-9 could not be clearly
identified on these zymograms of murine skin. However,
we did observe MMP-9 activation in HT1080 cell culture
supernatant after incubation with SAK and huPlg (data
not shown).
Zymograms of day 3 lesions (2 representative lesions
per group) showed a higher ratio of active/total MMP-2
Figure 4 (See legend on next page.)
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Figure 4 Infectious skin lesions at day 3 after subcutaneous infection with S. aureus Xen36. A. Macroscopic aspect of day 3 lesions. More
open lesions with skin rupture are observed in α2AP KO/huPlg mice, compared to WT/null mice (P <0.01). B. Hematoxyllin-eosin staining of
lesional skin from WT/null mouse showing a small abscess collection (arrows) without disruption of overlying skin (*). C. Hematoxyllin-eosin
staining of lesional skin from α2AP KO/huPlg mouse showing a large, less well-defined abscess collection (arrows), with extension (arrowheads) from
the initial infection site both towards the overlying skin (*) (with resulting skin disruption and crust formation) and towards the underlying subdermal
tissue and muscularis. D-E. Martius Scarlet Blue staining of the same lesion reveals a zone of fibrin deposition (F, red) at the periphery of the
initial abscess site (arrows), but the infection has spread past this border of fibrin, through collagen fibers (blue), into underlying tissue
layers (arrowheads).
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mice (Figure 7B). Increased MMP-9 expression and activ-
ity was observed in all infected skins compared to normal
skin, with a similar higher ratio of active/total MMP-9 in
the α2AP KO/huPlg group compared to control WT/null
mice (Western blot, Figure 7C).
Discussion
We evaluated the role of SAK-mediated plasminogen acti-
vation in a subcutaneous S. aureus skin infection model in
mice. Our results demonstrate that plasmin generation by
SAK increased spreading and hampered bacterial clear-
ance of S. aureus in infected skin, increased tissue proteo-
lytic MMP activity, and resulted in more pronounced
tissue damage, as noted by more open skin lesions. TheseA
C
Figure 5 Species-selectivity and fibrin-specificity of staphylokinase. A
(huPlg). Plasmin generation by adding SAK (6.25 nM) to either huPlg (0.25
(0.25 μM) with huPlg (0.05 μM or 20% of the muPlg concentration, compara
huPlg expression). Plasmin generation was quantitated by conversion of the c
reader at 405 nm. Mean and SD from 3 independent experiments. B. Plasmin
added to muPlg (0.25 μM), highlighting that low levels of huPlg in a b
generation. Mean and SD from 3 independent experiments. C-D. The c
inhibition by alpha-2-antiplasmin (α2AP) in the presence of fibrin analo
(0.25 μM) and huPlg (0.05 μM); with or without α2AP (0.125 μM) and e
(CNBr) 10 nM and 100 nM, respectively). Mean and SD from 3 indepenfindings were enhanced in the absence of the plasmin in-
hibitor α2AP, demonstrating a role for host α2AP in the
containment of S. aureus infections.
Strengths of our model are the use of a S. aureus strain
derived from a human infection in healthy mice, and the
non-invasive follow-up of bacterial spreading by biolumin-
escence. The use of an adenoviral vector encoding huPlg
resulted in plasma huPlg levels similar to those attained in
transgenic huPlg mice [12]. Our in vitro data confirm that
these huPlg concentrations in mice are sufficient to over-
come the species-selectivity of SAK and to mimic the
phenotype of SAK-mediated huPlg activation in the sub-
cutaneous infection model.
Our results are in line with previous results showing
that spreading through tissue barriers can be mediatedB
D
. Species-selectivity of staphylokinase (SAK) for human plasminogen
μM), murine plasminogen (muPlg 0.25 μM), or a mixture of muPlg
ble to the level of huPlg in murine plasma after adenoviral-mediated
hromogenic substrate S-2403 and assessed in a microtiter plate ELISA
generation by a preformed equimolar mixture of SAK with huPlg,
ackground of muPlg can induce efficient SAK-dependent plasmin
omplex of SAK with human plasmin (SAK-huPli) is protected from
gues. Plasmin generation by SAK (6.25 nM) in a mixture of muPlg
ither in the absence or presence of Fg(CNBr) (C. and D. for Fg
dent experiments.
Figure 6 SAK-huPli complex is protected from inhibition by
α2AP in the presence of S. aureus bacterial surfaces. S. aureus
bacterial surfaces enhance SAK-mediated plasmin generation and
partially protect the SAK-huPli complex from inhibition by α2AP. Plasmin
generation by SAK (6.25 nM) in a mixture of murine (0.25 μM)
and human (0.05 μM) plasminogen, with or without α2AP (0.125 μM)
and in the absence or presence of washed SAK-negative S. aureus LS-1
EP (OD600 2.0, 15% vol/vol). Plasmin generation was quantitated by
conversion of the chromogenic substrate S-2403 and assessed in
a microtiter plate ELISA reader at 405 nm. Mean and SD from 3
independent experiments. *denotes P < 0.05, **P < 0.01.
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can degrade several extracellular matrix components, but
not collagens [31]. Yet, we show that SAK-mediated plas-
min activity can lead to secondary activation of gelatinases
in mouse skin extracts, which may contribute to the pro-
teolytic activity necessary for dissemination through tissue.
Although we observed more proteolytic activity and
increased lesion dimensions in α2AP KO/huPlg groups,
we did not observe systemic spread nor mortality after
subcutaneous inoculation of S. aureus. However, systemic
dissemination was common when using a neutropenic
mouse model of S. aureus skin infection, as recently
shown [10]. This is in agreement with the clinical observa-
tion that skin infections by S. aureus infrequently lead to
systemic dissemination, unless there is an underlying vul-
nerability of the patient. In immunocompetent mice (and
patients), staphylococcal skin and soft tissue infections aremainly characterized by abscess formation, and bacteria
that do reach the systemic circulation or distant organs
are rapidly cleared.
The predominantly local effect of SAK-mediated plasmin
activity without affecting the severity of systemic symp-
toms is also in contrast with the findings by Sun et al. [12],
demonstrating that streptokinase increased mortality of
Group A streptococcal infection in a skin infection model
in huPlg transgene mice. Importantly, streptokinase is in-
sensitive to α2AP inhibition, in contrast with the SAK-
huPli complex that is rapidly inactivated by α2AP. Our
results confirm previous findings that fibrin protects the
SAK-huPli complex from inactivation; and a similar pro-
tective effect was noted from bacterial surfaces [8,32,33].
This may explain why SAK-mediated plasmin has more
localized effects compared to streptokinase-induced plas-
min. SAK-induced proteolysis is thus confined to the im-
mediate surroundings of the site of infection, where high
concentrations of fibrin and bacteria prevent inactivation,
but is rapidly neutralized further away from the abscess
site. In contrast, streptokinase-activated plasmin may have
a larger potential for systemic effect because of its resist-
ance to α2AP.
To explore whether inhibition by α2AP accounts for
the more localized effect of SAK compared to strepto-
kinase, we studied the impact of the genetic absence of
α2AP on the characteristics of S. aureus skin infection.
Indeed, α2AP KO was associated with larger lesion sizes,
compatible with a protective role of α2AP in tempering
the proteolytic effect of SAK-mediated plasmin. The lar-
ger lesion size in α2AP KO/null mice, lacking huPlg ex-
pression, is likely explained by activation of murine
plasminogen, bound to surface plasminogen receptors of
S. aureus, by host plasminogen activators. Different surface
plasminogen receptors have been described in S. aureus,
such as α-enolase, inosine 5’-monophosphate dehydrogen-
ase, ribonucleotide reductase subunit 2, triose phosphate
isomerase, surface immunoglobulin-binding protein and
extracellular fibrinogen-binding protein [33-35]. These
surface plasminogen receptors are not selective for huPlg
and constitute a common theme across different bacterial
and fungal organisms for the degradation of extracellular
matrix and immune evasion [35,36]. The resulting surface-
bound plasmin activity is less sensitive to inhibition by
plasma protease inhibitors, hence a slower but consistently
larger expansion of the lesion occurs in the α2AP KO/null
group compared to WT/null controls. The role of host
α2AP in limiting bacterial spreading was confirmed in add-
itional experiments where a SAK-negative strain (S. aureus
LS-1 EP) was used to infect α2AP KO and α2AP WT mice.
As α2AP gene deficiency does not impair fibrin generation,
the initial fibrin deposition surrounding the abscess was
comparable in both groups. However, at a later time point
the absence of the main plasmin inhibitor led to increased
AB
C
Figure 7 Gelatinase activation by SAK in skin tissue. A. Gelatin zymogram showing pro-MMP-2 and active MMP-2 in murine skin and subcutaneous
tissue protein extract after incubation with staphylokinase (SAK) and human plasminogen (huPlg). Activation with APMA, a chemical MMP-activator,
was used as a positive control. Quantitation of MMP-2 activation (active/total), data are mean ± SD from 3 independent experiments. *denotes P < 0.05.
B. Gelatin zymogram showing pro-MMP-2 and active MMP-2 in day 3 lesional skin samples. A sample from normal skin and an APMA-activated normal
skin extract are included as controls. Quantitation of MMP-2 activation (active/total), data are mean ± SD from 3 independent experiments. P for
trend <0.05. C. MMP-9 activation in day 3 lesional skin samples, assessed by Western blot. A sample from normal skin is included as control.
Quantitation of MMP-9 activation (active/total), data are mean ± SD from 3 independent experiments. P for trend <0.05.
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was a trend towards higher numbers of systemic infec-
tion in α2AP KO mice (4/25 vs 1/29 WT mice), we could
not demonstrate a strong effect of α2AP KO on systemic
spreading. Although α2AP is the predominant plasmin
inhibitor, other plasma inhibitors of fibrinolysis such as
alpha-2-macroglobulin may explain the absence of sys-
temic spread in α2AP KO/huPlg mice [32].
Interestingly, we also observed increased bacterial loads
in the presence of huPlg and/or in the absence of α2AP,
demonstrating that bacterial induced plasmin generation
helps to evade bacterial clearance by the host. It has been
shown previously that SAK binds to and inactivates hu-
man defensins, part of the innate immune defense againstbacteria [37]. SAK-induced plasmin activity can degrade
opsonizing complement components IgG and C3b [38],
thus protecting S. aureus from phagocytosis.
The production of SAK, a highly fibrin-specific plasmino-
gen activator [7,8], is particularly intriguing as S. aureus also
triggers fibrin formation through coagulase activity. The
role of staphylocoagulase-mediated fibrin deposition in
abscess formation is well established [3]. S. aureus also
possesses different binding proteins which interact with
fibrin(ogen) and extracellular matrix proteins [39]. It re-
mains to be resolved how coagulase-mediated fibrin de-
position and SAK-mediated fibrinolysis cooperate to
promote S. aureus virulence. Coagulase activity and the
resulting fibrin have been shown to shield S. aureus from
Peetermans et al. BMC Microbiology 2014, 14:310 Page 9 of 12
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this view, SAK allows S. aureus to generate fibrinolytic ac-
tivity that is protected by both the staphylothrombin- and
thrombin-generated fibrin from rapid neutralization by
host protease inhibitors. The resulting plasmin activity can
degrade the host’s fibrin as well as the S. aureus-mediated
fibrin and allow subsequent spreading of the growing bac-
terial colony. How S. aureus differentially regulates coagu-
lase and SAK activity remains unknown. Interestingly, SAK
expression is under control of the agr quorum sensing sys-
tem, suggesting that proteolytic activity is modulated by
bacterial density [40]. A regulated expression of SAK may
also explain the observed decreased virulence of genetically
engineered S. aureus strains with SAK overproduction, not
under control of its own promotor, as continuous and
high-level SAK production will interfere with coagulase ac-
tivity as a central virulence factor of S. aureus [9,10].
Conclusions
We show that SAK-mediated proteolytic activity in S.
aureus infected skin facilitates local spreading, increases
tissue damage of skin and reduces bacterial clearance by
the host. The underlying mechanisms involve protection
of the SAK-huPli complex associated with fibrin or bac-
terial surfaces, from rapid inhibition by α2AP. In turn,
active SAK-huPli may activate gelatinases, further pro-
moting degradation of the extracellular matrix. Overall,
this study shows the role of subversion of the host fi-
brinolytic system by SAK-producing S. aureus in migra-
tion through tissue barriers.
Methods
Bacterial strains
All animal experiments were performed with S. aureus
Xen36 (Caliper Life Sciences, Hopkinton, USA), a biolumin-
escent strain derived from the parental strain S. aureus
ATCC 49525 (Wright), a clinical isolate from a patient
with bacteremia. S. aureus Xen36 possesses a stable copy
of the modified Photorhabdus luminescens luxABCDE op-
eron at a single integration site on a native plasmid.
Clinical strains were collected from patients at the Univer-
sity Hospitals Leuven and originated from either skin infec-
tion or bacteremia secondary to a skin infection with
S. aureus. Laboratory strains included S. aureus Newman and
3 different congenic S. aureus LS-1 variants with different
SAK expression (LS-1 EP, LS-1 sak and LS-1 spasak)
[9].
All strains were stored in Brain Heart Infusion (BHI)
with glycerol at −80°C. Before use, strains were grown
overnight in Tryptic Soy Broth (TSB) at 37°C in aerobic
conditions. For subcutaneous infection, overnight cultures
were washed twice with PBS and diluted in PBS to an op-
tical density at 600 nm (OD600) of 2.0, corresponding to
2 × 109 CFU (colony forming units)/mL. CFU counts wereconfirmed by quantitative plating of the inoculum for each
experiment. SAK production was confirmed in the super-
natant of overnight cultures using an in-house developed
sandwich ELISA (MA-S20D11 +MA-S25F6/PA-RaSTAN
ELISA).
Animal experiments
All animal experimental procedures were approved by
the Ethics Committee of the KU Leuven.
Mouse strains
α2AP knock-out mice in C57BL/6 - S129Vj background
and their littermate wild type controls were used [41].
Adenoviral expression of huPlg
Because of the selectivity of SAK for huPlg, we studied
the role of SAK in a subcutaneous S. aureus infection
model after huPlg overexpression through adenoviral gene
transfer. An E1E3E4-deleted adenoviral vector inducing
hepatocyte-specific expression of huPlg (Adplasm) was
used. In this vector, the expression of huPlg is under con-
trol of the alpha-1-antitrypsin promoter and four copies of
the human Apo E enhancer [42]. Adnull, a similar adeno-
viral vector lacking an expression cassette was used as
control [43].
Male mice of 5-9 weeks were injected via the tail vein
with 5 × 1010 particles of either Adplasm or Adnull vector,
7-11 days prior to the subcutaneous infection. Hence, 4
different groups of mice were studied, which are identified
as α2AP KO/huPlg, α2AP KO/null, WT/huPlg and WT/
null, respectively.
Quantification of huPlg
Plasma concentrations of huPlg were quantitated by
ELISA and by a functional test specific for huPlg, allow-
ing measurement of huPlg concentrations in murine
plasma. The in-house developed sandwich ELISA, based
on the antibodies MA-42B12B4B2D and MA-34D3D10-
HRP does not cross-react with murine plasminogen.
The functional assay is based on the species-selectivity
of streptokinase, and measures plasmin generation with
a chromogenic substrate (S-2403, Chromogenix, Milano,
Italy) after addition of an excess of streptokinase (1000
IU/mL, Streptase, CSL Behring, Marburg, Germany).
Preliminary experiments showed reliable and stable ex-
pression of huPlg from day 7 up to 1 month (day 43) after
injection of adenoviral vector.
Skin infection model
Approximately 1 week post adenoviral injection, mice were
anesthesized with isoflurane and injected subcutaneously in
each flank with 100 μL containing 2 × 108 CFU of S. aureus
Xen36. Blood samples were collected on citrate (3.2%
sodiumcitrate, 10% vol/vol) by retro-orbital puncture, at
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were killed by heart puncture under high dose ketamine/
xylazine anesthesia. Largest diameter (a) and orthogonal
diameter (b) of skin lesions were measured with a caliper,
and skin lesion areas were calculated ((π/4)ab). Lesions
were then excised for histological analysis. Dimensions of
lesions from left and right flank were averaged per individ-
ual mouse. Spleen and kidneys were also collected for ana-
lysis of bacterial load.
One mouse died on day 4 in the α2AP KO/null group,
this subject was not included in analysis.
In a supplementary experiment, to study the effect of
host α2AP in staphylococcal skin infection, this subcuta-
neous infection model was carried out with SAK-negative
S. aureus LS-1 EP in α2AP KO or WT mice without previ-
ous adenoviral injection.
Bioluminescence imaging
Non-invasive follow-up of the local spreading of S. aureus
Xen36 was performed by means of bioluminescence im-
aging of the luciferase signal with a cooled CCD camera
(IVIS 100, Xenogen, Perkin-Elmer Company, Alameda,
USA). Mice were sedated with isoflurane and imaging was
performed for each lesion with an exposure time of 60 s.
Signal intensity was calculated with Living Image 2.5 ana-
lysis software (Xenogen) and denotes photons per second
through a defined region of interest (ROI), corresponding
to the infectious lesion. The same ROI was used for all in-
fectious lesions in all animals. Preliminary experiments
showed a correlation between bioluminescence signal in-
tensity and bacterial load of S. aureus Xen36 (Pearson r =
0.965, P = 0.0001). A fixed threshold was chosen for all
images and quantitation of the lesion size (pixels with sig-
nal above threshold) was performed with Image J software
(Image J, NIH, Bethesda, USA).
Histology
Paraffin-embedded tissue samples were used to prepare
10 μm thick sections. Routine histopathologic stainings
with hematoxyllin-eosin or Martius Scarlet Blue (for fibrin)
were performed.
Study of plasminogen activation by SAK
We studied the activation of plasminogen (human, mur-
ine, or a mixture of both) by SAK in the absence or pres-
ence of α2AP, fibrin and S. aureus bacteria. Human and
murine plasminogen were isolated from plasma by lysine
Sepharose affinity chromatography, as described previ-
ously [44]. SAK variant TS-162 was previously described
[45]. Murine α2AP was obtained from Abcam (Cambridge,
UK). SAK, α2AP and plasminogen were diluted in 0.1M
sodium phosphate buffer, pH 7.4, containing 0.05 M NaCl
and 0.01% Tween. Solid fibrin clots were formed upon
addition of bovine thrombin (1 U/mL) to human fibrinogen(200 μg/mL in 0.05 M Tris-HC1 buffer, pH 7.4, containing
0.038 M NaCl and 0.01% Tween 80) (Calbiochem, EMD
Millipore, Billerica, USA) (30 min, 37°C). CNBr-digested
murine fibrinogen (Fg(CNBr)) was prepared as published
[46]. In some experiments, S. aureus bacteria (OD600 2.0,
15% vol/vol; live or heat-killed at 60°C for 1h) were used
in the reaction mixture. In this case, bacteria were pelleted
by centrifugation before read-out of the absorbance at
405 nm (A405). Hydrolysis of the chromogenic substrate
S-2403 was used to monitor plasmin activity in a Bio-TEK
microtiter plate reader (Bio-TEK, Winooski, USA).
Blotting techniques
Gelatin zymography was used to study activation of the
gelatinase subfamily of matrix metalloproteinases (MMPs)
by the SAK-human plasmin complex (SAK-huPli). To this
end, tissue extracts of skin and subcutaneous tissue from
healthy C57BL/6 mice were prepared as described [47,48].
Briefly, tissue samples were snap frozen in liquid nitrogen.
Protein extraction was performed by homogenization with
glass beads in FastPrep24 (MP Biomedicals, Santa Ana,
USA) in the presence of extraction buffer (10 mM sodium
phosphate, pH 7.2, containing 150 mM NaCl, 1% Triton
X-100, 0.1% SDS, 0.5% sodium deoxycholate, and 0.2%
NaN3). After centrifugation, the protein concentration of
the supernatant was determined with the Bradford assay
(Bio-rad, Hercules, USA). The skin extracts were incu-
bated (2 h or 16 h, 37°C) with a mixture of 1.1 μM huPlg
and SAK (in a 1:10 molar ratio to huPlg).
Zymographic analysis of gelatinase activity was per-
formed on 10% Tris-glycine gels containing 0.1% gelatin
(Novex, Life Technologies, Carlsbad, USA).
We used MMP-containing medium from a HT1080
fibrosarcoma cell line (Sigma-Aldrich, St. Louis, USA) and
activation by APMA (4-amino-phenyl-mercuric acetate, a
chemical MMP-activator, Sigma-Aldrich) as a reference.
Preliminary experiments showed that plasmin also gener-
ated a gelatinolytic band on zymography. To irreversibly in-
activate plasmin prior to loading, samples were treated with
a 100-fold molar excess of D-Val-Phe-Lys-chloromethylke-
tone, dihydrochloride (Sigma-Aldrich) (15 min, room
temperature).
The lysis of the substrate gel (area × intensity) was quan-
titated by image analysis (Image J) [47].
Western blotting for murine MMP-2 and MMP-9 was
performed using a rabbit polyclonal antibody (NB200-193
for MMP-2, Novus Biologicals, Cambridge, UK and ab38898
for MMP-9, Abcam).
Statistical analysis
All calculations were performed using GraphPad Prism
5.0b (GraphPad Software, San Diego, USA). Data were
tested for normality and appropriate tests were used to
compare continuous variables between groups (t-test if
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bioluminescence data, values were compared at definite
time points with 1-way ANOVA, using t-test or Mann-
Whitney U test as post-test. For comparison of biolumin-
escence data over different time points and between
groups, 2-way ANOVA was used. For plasmin generation
experiments, A405 values were compared by repeated
measures 1-way ANOVA, using paired t-tests as post-test.
Quantitative data from blotting experiments were ana-
lyzed for trend using linear regression. P-values < 0.05
were considered statistically significant. In graphs, *de-
notes P < 0.05, **P <0.01, ***P < 0.001.Additional file
Additional file 1: Host α2-antiplasmin (α2AP) protects against
extension of S. aureus skin infection. Martius Scarlet Blue staining of
representative lesions from α2AP KO and α2AP WT mice, infected with
S. aureus LS-1 EP. In both genotypes, a peripheral zone of fibrin (F, red),
surrounding the abscess, can be appreciated on day 1. On day 3 how-
ever, less fibrin is observed in the abscess periphery of α2AP KO mice,
likely reflecting the disbalance between (normal) fibrin deposition and
(uninhibited) fibrinolysis at this later time point. Hence, α2AP gene defi-
ciency impairs sustained local containment of S. aureus infection.Abbreviations
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